Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
cbdMD ( (YCBD) ) has shared an update.
On March 30, 2026, cbdMD shareholders approved all proposals at the company’s 2026 annual meeting, including the election of seven directors and ratification of Cherry Bekaert LLP as independent auditor for the fiscal year ending September 30, 2026. A quorum was achieved with 54.6% of the 10.5 million outstanding shares represented in person or by proxy.
Investors also authorized a discretionary reverse stock split in a range of 1-for-2 to 1-for-10 to be implemented within a year, as well as several share issuance proposals tied to Series B and Series C convertible preferred stock, an equity line of credit agreement with C/M Capital Master Fund, LP, and the 2025 Equity Compensation Plan. These approvals give cbdMD expanded flexibility to raise capital and manage its capital structure, though the conversions and equity line could result in issuance exceeding 20% of current outstanding shares and significant dilution to existing shareholders.
The most recent analyst rating on (YCBD) stock is a Sell with a $0.61 price target. To see the full list of analyst forecasts on cbdMD stock, see the YCBD Stock Forecast page.
Spark’s Take on YCBD Stock
According to Spark, TipRanks’ AI Analyst, YCBD is a Neutral.
The score is held down primarily by weak financial performance (multi-year revenue decline, ongoing losses, and negative cash flow) and bearish technicals (price below key moving averages with negative MACD). The latest earnings call provides some offset via improving sequential sales, near-breakeven EBITDA, and strengthened liquidity, but margin pressure and regulatory risks remain.
To see Spark’s full report on YCBD stock, click here.
More about cbdMD
cbdMD operates in the consumer wellness sector, producing and marketing cannabidiol (CBD) and related cannabinoid products aimed at health, recovery, and everyday wellness users. The company focuses on building its brand and capital access on U.S. public markets, where shareholder approvals and stock-structure flexibility are critical to its ability to fund ongoing operations and strategic initiatives.
Average Trading Volume: 1,066,543
Technical Sentiment Signal: Sell
Current Market Cap: $7.79M
For detailed information about YCBD stock, go to TipRanks’ Stock Analysis page.